Moderna ' s combination skin cancer therapy receives FDA ' s breakthrough tag

Moderna Inc said on Wednesday its experimental personalised mRNA skin cancer vaccine in combination with Merck & Co Inc's drug Keytruda has received breakthrough therapy designation from U.S. regulators as an additional treatment for high risk patients. Shares of (NASDAQ: ) rise 2.5% to $164 after…#modernainc #mrna #merckcoinc #keytruda #fda
Source: Reuters: Health - Category: Consumer Health News Source Type: news